in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Pharma/fine chemicals roundup—8 April 2014
12:08 AM MDT | April 8, 2014 | Deepti Ramesh
FDA issues warning letter to GlaxoSmithKline’s API plant in Ireland The US FDA issued a warning letter on 18 March to the active pharmaceutical ingredient (API) manufacturing facility of GlaxoSmithKline (GSK; London) located at Carrigaline in the county of Cork, Ireland, for violations of cGMP. An FDA inspection from 18–23 October 2013 at the Carrigaline facility identified deviations from cGMP for the manufacture of APIs, FDA says. The warning letter was published in the FDA web site on 1 April. The FDA has conducted a detailed review of GSK's...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee